Telotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP
|
|
- Peter Merritt
- 5 years ago
- Views:
Transcription
1 Telotristat Ethyl (etiprate) : a new kid on the block Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine Tumour Unit - ENETS Centre of Excellence ROYAL FREE HOSPITAL, London,UK
2 IPSEN Honoraria for lectures Educational Grants for RFH NET Unit Advisory Board NOVARTIS Honoraria for lectures Educational Grants for RFH NET Unit Advisory Board LEXICON Advisory Board
3 Contents Refractory carcinoid syndrome Implications Current options Telotristat ethyl : Mode of action Summary of preclinical data and phase I data Phase II trials Phase III trials Positioning of Telotristat in NETs therapeutic algorithm
4 MIDGUT NETs (in 5% of bronchial NETs and 1% of pancreatic NETs) a. Carcinoid syndrome Flushing, diarrhoea, bronchospasm, Carcinoid heart disease % of patients with liver metastases 5% of patients with carcinoid syndrome do not have liver metastases b. Carcinoid crisis Severe symptoms of carcinoid syndrome + hypotension during procedures that involve GA, as well as in TAE, and when the patient is on inotropes Refractory Carcinoid syndrome : ongoing symptoms, despite maximum conventional doses of somatostatin analogues (SSTA)
5 Are my patient s symptoms really due to Refractory Carcinoid Syndrome? OTHER CAUSES OF DIARRHOEA Steatorrhoea Small bowel bacterial overgrowth Bile acid malabsorption Mesenteric ischaemia OTHER CAUSES OF FLUSHING Menopause Anxiety attacks Medications (morphine analogues)
6 Refractory Carcinoid Syndrome & risk for development and / or progression of CHD Multivariate model, in a prospective study of 252 patients. Development and progression of CHD were linked to 5-HIAA levels. 5-HIAA > 300 μmol/l is independent predictor for development and progression of CHD (2-3 fold increase in risk). The same risk was noted in patients with > 3 flushing episodes / day. Denney et al, J Am Coll Cardiol 1998 Moller et al, NEJM 2003 Bhattacharyya et al, Am J cardiol 2011
7 Carcinoid Heart Disease It represents the development of fibrotic plaques on the heart valves. It DOES NOT mean development of myocardial metastases. Reported in the past in 40-50% of patients with carcinoid syndrome,, recent prevalence : about 20%, (midgut NETs with hepatic or retroperitoneal metastases, ovarian NETs and bronchial NETs). Its development is associated with 30 50% reduction in the expected survival of those patients. The median survival improved from 1.5 years in the 1980s to 4.4 years in the late 1990s.
8 Gastrointestinal neuroendocrine tumors treated with high dose octreotide-lar: A systematic literature review Michael S Broder, David Beenhouwer, Jonathan R Strosberg, Maureen P Neary, Dasha Cherepanov, World J Gastroenterol 2015 Feb Octreotide LAR dose Results Valle et all (2001) Dose escalation Improvement of symptoms Woltering et all (2006) 20mg/30mg/60mg Flushing not controlled in 0% (20 mg), 11.1% (30 mg), vs 7.1% (60 mg), diarrhea not controlled in 0% of pts. (20 mg), 27.8% (30 mg), vs 30.8% (60 mg) groups Ferolla et all (2012) 30mg every 3 weeks Complete normalization 40% Partial symptom control in 60% Strosberg at all (2013) Wolin at all (2013) (phase III study with pasireotide) 30mg every 3 weeks 40mg / 60 mg 40mg 62% improvement of diarrhoea 56% improvement of flushing 27% symptoms improvement in month 6
9 Interferon Alpha for carcinoid syndrome symptoms control RFH Interferon Data 24 pts, in combination with SSTA - Diarrhoea improved 45% - Flushing improved in 54% Of the 19 patients given alpha-interferon in combination with octreotide, 72% showed significant reduction in urinary 5- HIAA for a median of 10 months. A symptomatic improvement was seen in 49%. The combination was well tolerated. - No statistically significant decrease of 5-HIAA levels - 27% of patients discontinued treatment at 3 months, due to AE Mirvis et al, Anticancer Research 2015 Janson & Oberg, Acta Oncol 1993
10 EVEROLIMUS FOR REFRACTORY CARCINOID SYNDROME Control of carcinoid syndrome with everolimus (CASE REPORT) Capdevilla J et al. Ann Oncol 2011 CgA 5-HIAA After a month of treatment, the symptoms of carcinoid syndrome improved with a reduction in the flushing episodes to 1 2 per day, an improvement in diarrhea and a significant decrease in 5-HIAA levels (up to 60%). Symptomatic Control of Neuroendocrine Tumours with Everolimus. Bainbridge et al, Horm Cancer 2015 Everolimus plus octreotide LAR resulted in greater reductions in serum chromogranin A (p treatment=0 0041) and urine 5- hydroxyindoleacetic acid (p treatment <0 0001) compared with placebo plus octreotide LAR. RADIANT-2, Pavel et al, Lancet /10 patients who were syndromic had improvements in symptomology, with a mean duration of symptom control 13.9 months. 6/10 had reduced stool frequency, 3/7 had a reduction of asthenia, and 5/7 had reduced frequency and severity of flushing. Sixty percent of patients experienced any grade toxicities, including the following: 40% grade 1/2 stomatitis, 7% grade 3/4 stomatitis, 20% grade 1/2 rash, 13% diarrhoea, and one case of pneumonitis
11 Control of carcinoid syndrome symptoms with PRRT RFH PRRT data 35 patients Percentages of patients who reported improvement in pain and diarrhoea score after PRRT. Saima Khan et al. J Nucl Med 2011 Koffas et al, ENETS & DDW 2016
12 No enough data for sunitinib or systemic chemotherapy for symptoms control in refractory carcinoid syndrome
13 Transarterial Hepatic Embolization and Chemoembolization Symptomatic benefit (40-80%) Partial response : ~ 50%? Survival benefit Brown et al J Vasc Interv Radiol 1999;10(4): Chamberlain et al J Am Coll Surg 2000;190: Morbidity (carcinoid crisis, fever, pain, hepatic failure, intestinal ischaemia) Mortality i.v. octreotide infusion pre- and post therapy Careful selection of patients Toumpanakis et al, Best Pract Res Clin End Metab 2007
14 Phase III study of pasireotide LAR vs octreotide LAR in patients with metastatic midgut NET Blinded treatment period of 6 months NET patients with carcinoid syndrome symptoms inadequately controlled by maximum doses of currently available SSAs 1:1 randomisation Pasireotide LAR 60mg IM every 28 days x 6 months with dose to 40mg for tolerability (n=53) Octreotide LAR 40mg IM every 28 days x 6 months with dose to 30mg for tolerability (n=57) Primary endpoint: symptom control (month 6) Secondary endpoints: tumour response, PFS, safety Trial was terminated early based on interim analysis demonstrating futility for primary endpoint (symptom response at month 6) Wolin et al, Drug Des Devel Ther Sep 3;9:
15 It seems that THERE IS an unmet need
16 Telotristat etiprate: A peripherally-acting serotonin synthesis inhibitor Telotristat etiprate is a novel, orallydelivered inhibitor of tryptophan hydroxylase (TPH) that reduces serotonin production: Absorbed into peripheral circulation Does not cross the bloodbrain barrier Lapuerta P, et al. Clinical Investigation (Lond.) 2015; 5(5):
17 Telotristat etiprate : Molecular structure Telotristat etiprate is an ethyl ester pro-drug which is hydrolyzed to its active moiety LP both in vivo and in vitro Telotristat etiprate conversion Lapuerta P, et al. Clinical Investigation (Lond.) 2015; 5(5):
18 Telotristat etiprate: Mode of action TPH Catalyzes the First Step of Serotonin Synthesis Tryptophan Hydroxylase (TPH) Tryptophan Telotristat Etiprate 5-Hydroxytryptophan 5-HI AA (5-Hydroxyindoleacetic acid) Serotonin (5-Hydroxytryptamine, 5-HT) TPH catalyzes the first step of serotonin synthesis 2013 Lexicon Pharmaceuticals, Inc. Slide 10
19 Ιn addition to SSA, telotristat etiprate inhibits serotonin production and alleviates symptoms Serotonin hormonal syndrome flushing, diarrhoea... 5-HIAA Urine Serotonin Tryptophan- Hydroxylase Tryptophan 5-Hydroxytryptophan (5-HTP) NET-Cell Telotristat etiprate SSTR 5-HIAA: 5-hydroxyindole acetic acid SSA somatostatin analogue SSTR somatostatin receptor Serotonin (5-HT) SSA
20 Preclinical summary Reduction of peripheral serotonin levels in KO mice did not adversely affect physiologic function Telotristat etiprate reduces peripheral serotonin levels without affecting brain serotonin levels
21 Summary of phase 1 clinical results Single and multiple dose phase 1 studies involving 88 subjects demonstrated that telotristat etiprate was tolerated up to the highest dose tested over 14 days (1,500 mg) Adverse events were minimal, generally mild in intensity, and evenly distributed throughout all dose groups Statistically significant reductions in biomarkers of interest were observed at doses from 500 mg to the maximum dose of 1,500 mg (500 mg TID): 20-30% reduction in blood serotonin 50-60% reduction in 24-hour urinary 5-HIAA Lapuerta P et al. Clin. Invest. (Lond.) 2015;5(5): Lexicon pharmaceutical, 2013
22 Telotristat etiprate: phase 2 studies Two Phase 2 studies examined the safety and efficacy of telotristat etiprate in patients with carcinoid syndrome not adequately controlled by somatostatin analogues Inadequate control was defined as average bowel movement frequency 4 episodes per day during a baseline assessment period 1 2 LX conducted in the USA, placebo- controlled, 28- day study with several different doses: 150 mg, 250 mg, 350 mg and 500 mg, TID LX conducted in Europe, open-label, 12-week study with titrated dose level: 150 mg, 250 mg, 350 mg and 500 mg, TID Lapuerta P, et al. Clinical Investigation (Lond.) 2015; 5(5): Kulke MH, et al. Endocr. Relat. Cancer 2014 ; 21 (5): Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
23 LX : Endpoints Primary efficacy analysis Reduction in bowel movements (baseline 4-10 bowel movements per day) Secondary efficacy analyses Reduction in 24-hour urine 5-HIAA (u5-hiaa), a biomarker for serotonin synthesis Report of adequate relief Flushing, pain, bloating, urgency, stool consistency, nausea Kulke MH, et al. Endocr. Relat. Cancer 2014 ;21(5):
24 LX : Positive top-line results with telotristat etiprate Clinical Response (at least 30% reduction in bowel movements for at least 2 weeks) Biochemical Response (at least 50% reduction or normalization in u5- HIAA) Adequate Relief at Week 4 Placebo Telotristat etiprate n R R/n n R R/n 5 0 0% % 5 0 0% % 4 0 0% % R The = number results of in patients terms of achieving biochemical a response response, clinical response and n patient = number reported of patients adequate available relief for analysis of symptoms were reported only in telotristat etiprate treatment group and not in the placebo group Lapuerta P et al. Clinical Investigation (Lond.) 2015; 5 (5): Kulke MH, et al. Endocr. Relat. Cancer 2014 ;21(5):
25 LX : Phase 2 European open label study in carcinoid syndrome Primary objective Evaluate the safety and tolerability of Telotristat etiprate in patients with symptomatic carcinoid syndrome Secondary objectives Assess the change in: Number of daily bowel movements Stool form/consistency Urgency to defecate Sensation/severity of nausea Subjective global assessment of symptoms associated with carcinoid syndrome Subjective assessment of abdominal pain or discomfort Number of cutaneous flushing episodes Urinary 5-HIAA levels Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
26 LX : Patients experienced reductions in bowel movement frequency Mean BM frequency -43.5% change from BL at Weeks There was a significant reduction in bowel movement frequency, from a baseline of 5.9 to a mean of 3.3 BMs/day at Week (p < 0.001) Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
27 Mean Stool Form (6-point scale) LX : Stool consistency weekly average -19.5% change from BL at Weeks Scale 0: None, 1:Hard, 2:Firm, 3:Soft, 4:Loose, 5: Watery Stool consistency improved significantly (p < 0.05). Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
28 Mean Daily Flushing Episodes LX : Flushing weekly average -36.6% change from baseline at Weeks Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
29 Mean Daily Abdominal Pain/Discomfort Score (100 mm VAS) LX : Mean abdominal pain/discomfort Mean Abdominal Pain/Discomfort -18.4% change from baseline at Weeks Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
30 Mean U5-HIAA (mg/24hours) LX : Urinary 5-HIAA weekly average Mean U5-HIAA value -71.9% change from baseline at Wks Pavel M, et al. J. Clin. Endocrinol. Metab 2015; 100(4):
31 Messages from phase 2 studies 1 Telotristat etiprate significantly reduced BM frequency and associated abdominal pain in patients with breakthrough symptoms of carcinoid syndrome 2 Telotristat etiprate provided clinically meaningful reductions in flushing episodes 3 Telotristat etiprate significantly decreased serotonin levels, as determined by 24- hour urinary 5-HIAA, in patients with inadequately controlled carcinoid syndrome 4 Reduction of carcinoid syndrome associated symptoms correlates with reduction in 5-HIAA, which is consistent with inhibition of tumor serotonin production, the known mechanism of action of telotristat etiprate 5 Clinical response was not dependent on the type, or dose, of concomitant SSA 6 There is no evidence of loss of response to prolong (up to 12 weeks) telotristat etiprate therapy
32 Telotristat ethyl: phase 3 studies
33 TELESTAR LX LX LX (Telotristat Etiprate for Carcinoid Syndrome Not Adequately Controlled on Somatostatin Analogue Therapy) ) TELECAST (Telotristat Etiprate for Carcinoid Syndrome Therapy) TELEPATH (Telotristat Etiprate Expanded Treatment for Patients with Carcinoid Syndrome)
34 TELESTAR Phase 3 Study Design 3- to 4- week runin (n=135) Run in: Evaluation of bowel movement (BM) frequency 1:1:1 R Placebo TID (n=45) Telotristat etiprate 250 mg TID (n=45) Telotristat etiprate 500 mg TID* (n=45) Telotristat etiprate 500 mg TID Evaluation of primary endpoint: Reduction in number of daily BMs from baseline (averaged over 12- week double-blind treatment phase) All patients required to be on SSA at enrollment and continue SSA therapy throughout study period
35 TELESTAR results : Reduction in Mean Daily Bowel Movement Frequency at Baseline and Week 12 29% 35% 17% Mild nausea: 15% Mild depression: 15-20%% n=35 n=36 n=37 35
36 Mean u5-hiaa Change From Baseline, mg/24 Hours Phase III TELESTAR Mean change in u5-hiaa (mg/24 hours) from baseline to week Placebo (n=29) Telotristat ethyl 250mg (n=32) Telotristat ethyl 500mg (n=31) All patients continued SSA therapy throughout the study period. Data include only patients for whom both baseline and week 12 assessments were available. Wilcoxan rank-sum test showed significant differences for each telotristat ethyl dose vs placebo (P<0.001) Baseline 5-HIAA levels across treatment arms ranged from mg/24 h
37 Phase III TELESTAR: AEs of interest 1 Category Placebo* Telotristat ethyl 250 mg* Telotristat ethyl 500 mg* Patients, n Total Nausea, n (%) 5 (11.1) 6 (13.3) 13 (28.9) 24 (17.8) Severe nausea, n (%) 1 (2.2) 1 (2.2) 0 2 (1.5) Discontinuation due to nausea, n (%) 1 (2.2) (0.7) Depression, n (%) 3 (6.7) 1 (2.2) 6 (13.3) 10 (7.4) Depressed mood, n (%) 0 1 (2.2) 2 (4.4) 3 (2.2) Severe depression or depressed mood, n Discontinuation due to depression or depressed mood, n *All patients continued SSA therapy throughout the study period.
38 Phase III TELESTAR: conclusions Telotristat ethyl significantly reduced BM frequency in patients with carcinoid syndrome inadequately controlled with SSA therapy 1 Patients receiving telotristat ethyl demonstrated more durable responses compared with placebo and the difference was statistically significant 1 Telotristat ethyl significantly decreased 24-hour u5-hiaa in a dose-dependent manner in patients with inadequately controlled carcinoid syndrome 1 Reductions in flushing and abdominal pain were greater on treatment with telotristat ethyl (not statistically significant) 1 Inhibition of u-5hiaa is consistent with the proposed mechanism of action of telotristat ethyl Telotristat ethyl was well tolerated in the TELESTAR study 1
39 RANDOMISATION LX TELEPATH Study LX TELECAST Study design Patients with histopathologicallyconfirmed, well-differentiated, metastatic NET; with history of carcinoid N=60 Phase 3 Telotristat etiprate 250 mg + placebo TID orally Telotristat etiprate 500 mg + placebo TID orally Telotristat etiprate 500 mg TID + SSA syndrome Placebo TID orally Double- blind Treatment phase Open-label Extension phase Primary endpoint: Incidence of treatment-emergent AEs, % change in urinary 5-hydroxyindoleacetic acid level
40 TELECAST Primary Safety Endpoint: Incidence of Treatment-emergent Adverse Events Telotristat Telotristat Category, n (%) Placebo tid ethyl ethyl (n=26) 250 mg tid 500 mg tid (n=25) (n=25) Any TEAE 21 (80.8) 25 (100) 21(84.0) Gastrointestinal disorders 15 (57.7) 16 (64.0) 9 (36.0) General disorders and administration-site conditions 6 (23.1) 7 (28.0) 4 (16.0) Infections and infestations 5 (19.2) 8 (32.0) 4 (16.0) Treatment-related TEAEs 8 (30.8) 10 (40.0) 11 (44.0) Serious TEAEs* 5 (19.2) 1 (4.0) 2 (8.0) Serious treatment-related TEAEs Study discontinuation due to TEAEs 1 (3.8) 2 (8.0) 0 TEAE resulting in death *Serious TEAEs: placebo - disease progression, cerebrovascular accident, bronchiectasis, dyspnea, and urethral stent insertion; telotristat ethyl 250 mg - disease progression; telotristat ethyl 500 mg - ascites and disease progression Discontinuations: placebo - disease progression; telotristat ethyl 250 mg upper abdominal pain, diarrhea; telotristat ethyl 500 mg - NA 40
41 TELECAST - Adverse Events of Interest Category, n (%) Depression-related TEAEs Depressed mood Decreased interest Depression Hepatic enzyme elevations Elevated gamma-glutamyl transferase Elevated alanine aminotransferase Placebo tid (n=26) 2 (7.7) 2 (7.7) 1 (3.8) Telotristat ethyl 250 mg tid (n=25) 1 (4.0) 1 (4.0)* (8.0) 1 (4.0) 1 (4.0) Telotristat ethyl 500 mg tid (n=25) 1 (4.0) (4.0) 3 (12.0) 1 (4.0) 0 Any gastrointestinal-related TEAE Abdominal pain Diarrhea Nausea 15 (57.7) 4 (15.4) 5 (19.2) 4 (15.4) 16 (64.0) 8 (32.0) 4 (16.0) 3 (12.0) 9 (36.0) 0 2 (8.0) 2 (8.0) *Patient was reported to have concomitant TEAEs of anemia and pyrexia that contributed to depressed mood. Patient had underlying depression that was treated with paroxetine at Baseline. All events of depression, nausea, and hepatic enzyme elevations were mild or moderate in intensity, and none resulted in treatment discontinuation. Gastrointestinal-related TEAEs were less frequent with telotristat ethyl 500 mg than with placebo or telotristat ethyl 250 mg. TEAE, treatment-emergent adverse event; tid, 3 times per day
42 TELESTAR / TELECAST durable response Durable response defined as 30% reduction in bowel movements frequency for 50% of doubleblind study period Placebo (n=26) 250 mg (n=25) 500 mg (n=25) Treatment difference durable response rate (95% CL) 0.4 (0.2, 0.6) 0.4 (0.2, 0.6) Pavel et al. NANETS 2015 p-value
43 TELECAST summary and conclusion Both primary safety and efficacy endpoints of the DBT period of the TELECAST study were met The safety results of this study support those observed in previous trials: Depression-related events and elevations in hepatic enzymes did not lead to study discontinuation There was a statistically significant reduction in u5-hiaa levels and BM frequency with telotristat ethyl in patients with CS, consistent with the results of the TELESTAR Phase 3 study Durable response was observed in 40% of patients receiving telotristat ethyl 250 mg tid and telotristat ethyl 500 mg tid Telotristat ethyl represents a new potential treatment approach for patients with CS
44 LX TELEPATH Design Patients from studies: LX LX LX (TELESTAR) LX (TELECAST) could continue or be switched on telotristat etiprate in the LX study N=160* Phase 3 Telotristat etiprate 250 mg daily orally Telotristat etiprate 500 mg daily orally Primary endpoint: incidence of treatmentemergent AEs at week 50 Study duration This study is a roll-over extension study (compasionate use) for patients in the TELESTAR and TELECAST studies and earlier phase 2 studies
45 Telotristat and Carcinoid Heart Disease Two patients with CHD after TVR (mechanical and biological prosthesis) After telotristat was commenced: Significant decrease in 5-HIAA levels No recurrence/new valve involvement by CHD in the 1 st patient Regression of TVR in the 2 nd patient (moderate TR to mild-mod TR) Dr Simona Glasberg Neuroendocrine Tumors Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (anecdotal data) Two patients, with CHD In one patient with moderate TR; 5-HIAA decreased substantially and CHD remained stable, not requiring valve replacement. The other underwent replacement of TV and PV with bioprosthetic valves and developed early recurrence of valvulopathy on both valves. Commenced on telotristat, and whilst a a re-operation was considered due to mod-severe TR and mod PR, there has been no progression on telotristat and surgery has not been deemed necessary. Dr Jerome S Zacks, Center for Carcinoid and Neuroendocrine Tumors, Icahn Medical School at The Mount Sinai Medical Center, New York, NY (ENETS 2016)
46 Telotristat ethyl: positioning in NETs therapeutical algorithm
47 Exclude other causes Carcinoid syndrome Resistant to SSTA No radiological progression Radiological progression Optimize SSTs Add telotristat Ethyl Add Interferon-A TAE Debulking surgery PRRT? Everolimus Predominantly Liver disease TAE? SIRT
48 Carcinoid syndrome With Carcinoid Heart Disease at presentation Without Carcinoid Heart Disease at presentation Somatostatin Analogues Maximum dose of somatostatin analogues +/- Telotristat Ethyl If 5-HIAA still > 300 Add Telotristat Ethyl
49 Thank you
Discovering Breakthrough Treatments for Human Disease. Discovering Breakthrough Treatments for Human Disease
Patient Reported Outcomes in Oncology Trials Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Discovering Breakthrough Treatments for Human Disease Discovering Breakthrough Treatments
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationImpact of Functioning Metastatic Neuroendocrine Tumors
Clinical Overview and Treatment Advances in Carcinoid Syndrome Sponsored by Lexicon Pharmaceuticals Impact of Functioning Metastatic Neuroendocrine Tumors Evaluation & Management 1 Presentation objectives
More informationHot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ
Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationPRESS RELEASE. Beaumont et al. Pancreas Journal 2012 ; 41(3) : / 5
PRESS RELEASE Ipsen receives approval from European Commission for Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analogue
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationClinical Development in the Treatment of Carcinoid Syndrome. Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer
Clinical Development in the Treatment of Carcinoid Syndrome Pablo Lapuerta, MD Executive Vice President and Chief Medical Officer Carcinoid Syndrome Heart Pulmonic and tricuspid valve thickening Stenosis
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationAUSTRALIAN PRODUCT INFORMATION 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse
More informationTUMORES NEUROENDOCRINOS. Miguel Navarro. Salamanca
TUMORES NEUROENDOCRINOS Miguel Navarro. Salamanca Introduction to Neuroendocrine Tumours (NETs) NETs are relatively RARE At least 40 different entities are described arising in different organs. Different
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationOVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS
OVERVIEW OF THE DIAGNOSIS AND TREATMENT OF GI NETS Dr Christos G. Toumpanakis MD PhD FRCP FEBGH Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University College of London Neuroendocrine
More informationLe target therapy nei Tumori Neuroendocrini
Le target therapy nei Tumori Neuroendocrini Take home messages Franco Grimaldi SOC Endocrinologia e Malattie del Metabolismo Nutrizione Clinica Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
More informationJaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xermelo (telotristat) Page 1 of 5 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xermelo (telotristat) Prime Therapeutics will review Prior Authorization requests
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationEverolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors
CHEST Original Research Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 Study LUNG
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationAn Overview of NETS. Richard R.P. Warner M.D
An Overview of NETS Richard R.P. Warner M.D Diagnosis and Treatment Approaches Carcinoid (and other NETs) not as benign as originally described 13-50% of all carcinoids have distant metastases when first
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationStrategies in the Management of Neuroendocrine Tumors. Dr. Jean Maroun Dr. Elena Tsvetkova
Strategies in the Management of Neuroendocrine Tumors Dr. Jean Maroun Dr. Elena Tsvetkova 1 A ZORSE 2 Neuroendocrine Tumour Classification Neuroendocrine Tumours Carcinoid Tumours Pancreatic Neuroendocrine
More informationCase Presentation. Marianne Ellen Pavel. Charité University Medicine Berlin. ESMO Preceptorship on GI Neuroendocrine Tumors
Case Presentation Marianne Ellen Pavel Charité University Medicine Berlin ESMO Preceptorship on GI Neuroendocrine Tumors Session 3; Singapore November 2, 2012 06.11.2012 Medical History 46-year-old man
More informationPrinciples of diagnosis, work-up and therapy The Gastroenterologist s role
Principles of diagnosis, work-up and therapy The Gastroenterologist s role Dr. Christos G. Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior Lecturer University
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationPharmacy Prior Authorization Somatostatin Analogs Clinical Guideline
Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce
More informationTelotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy in the TELECAST
Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy in the TELECAST Phase 3 Trial Authors: Marianne Pavel 1,2, David J. Gross 3, Marta Benavent 4,5, Petros Perros 6, Raj Srirajaskanthan 7, Richard
More informationSandostatin LAR. Sandostatin LAR (octreotide acetate) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.09 Subject: Sandostatin LAR Page: 1 of 5 Last Review Date: March 16, 2018 Sandostatin LAR Description
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationNew Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer
New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant
More informationSelf-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues - the role for specialist dietitians and nurses
Self-reported side effects in neuroendocrine tumour (NET) patients prescribed somatostatin analogues - the role for specialist dietitians and nurses Tara Whyand BSc MSc Neuroendocrine Tumour Research &
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationOctreotide LAR in neuroendocrine tumours a summary of the experience
Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie
More informationLu 177-Dotatate (Lutathera) Therapy Information
Lu 177-Dotatate (Lutathera) Therapy Information Information for Lu 177-dotatate therapy also known as Lutathera, for the treatment of metastatic midgut neuroendocrine tumor and other metastatic neuroendocrine
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationNeuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC
Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy
More informationSystematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors
At the Cutting Edge Received: February 29, 2016 Accepted: April 12, 2016 Published online: April 16, 2016 Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors Adrian Lee
More informationFRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS)
FRANKLY SPEAKING ABOUT CANCER: NEUROENDOCRINE & CARCINOID TUMORS (NETS) Gilda s Club Quad Cities November 5 th, 2018 Joseph Dillon, MD Neuroendocrine Tumor Clinic University of Iowa Hospitals & Clinics
More informationGEP NET: algoritmo terapeutico. Dottor Nicola Fazio
GEP NET: algoritmo terapeutico Dottor Nicola Fazio Basi per il trattamento Caratteristiche del paziente Caratteristiche del tumore P.S., sindrome, comorbidità Differenziazione, Ki-67 Imaging morfologico
More informationSurvivorship care of Neuroendocrine Tumours(NETs) from a Specialised Nursing Perspective
Survivorship care of Neuroendocrine Tumours(NETs) from a Specialised Nursing Perspective Avril Hull, Auckland District Health Board, New Zealand Kate Wakelin, Unicorn Foundation, Australia Philippa Davies,
More informationGastrointestinal neuroendocrine tumors treated with high dose octreotide-lar: A systematic literature review
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v21.i6.1945 World J Gastroenterol 2015 February 14; 21(6): 1945-1955 ISSN 1007-9327
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationNeuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy
Neuroendocrine Tumors Positron Emission Tomography (PET) Imaging and Peptide Receptor Radionuclide Therapy Lawrence Saperstein, M.D. Assistant Professor of Radiology and Biomedical Imaging Chief, Nuclear
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationThe Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review
Gastrointestinal Cancer The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review MICHAEL MICHAEL, a ROCIO GARCIA-CARBONERO, b MATTHIAS M. WEBER, c CATHERINE
More informationEverolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA
Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression MTA 1 st Appraisal Committee meeting Cost Effectiveness Committee
More informationTreatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece
Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationCollaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors
Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic Neuroendocrine Tumors Collaborative Practice in the Management of Patients With Gastrointestinal and Pancreatic
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationPeptide Receptor Radionuclide Therapy using 177 Lu octreotate
Peptide Receptor Radionuclide Therapy using 177 Lu octreotate BLR Kam, Erasmus Medical Centre, Rotterdam DJ Kwekkeboom, Erasmus Medical Centre, Rotterdam Legal aspects As 177 Lu-[DOTA 0 -Tyr 3 ]octreotate
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationLiver Embolization with Trisacryl Gelatin Microspheres (Embosphere) in Patients with Neuroendocrine Tumors
Acta Radiologica ISSN: 0284-1851 (Print) 1600-0455 (Online) Journal homepage: https://www.tandfonline.com/loi/iard20 Liver Embolization with Trisacryl Gelatin Microspheres (Embosphere) in Patients with
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationDrafting a Coverage Authorization Request Letter
Drafting a Coverage Authorization Request Letter The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations,
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationGrade 2 Ileum NET with liver and bone metastasis
Grade 2 Ileum NET with liver and bone metastasis BERNARDO MARQUES ENDOCRINOLOGY DEPARTMENT PORTUGUESE INSTITUTE OF ONCOLOGY - COIMBRA April 2018, Lugano, Switzerland JPB, male, 67 years old April 2015
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationMedullary Thyroid Carcinoma: New Therapies and Trials
Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University
More informationPRESS RELEASE. Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
PRESS RELEASE Advanced Accelerator Applications Receives US FDA Approval for LUTATHERA for Treatment of Gastroenteropancreatic Neuroendocrine Tumors First-in-class Therapy Demonstrated 79% Improvement
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationNICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationXP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED.
XP23829 PHASE 2 PSORIASIS TRIAL PRELIMINARY TOPLINE DATA PRESENTATION SEPTEMBER 15, 2015 COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR DISCLAIMER These slides and the accompanying oral
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationA case of persistent diarrhoea. Dr. Miles Levy, Dr. Jenny Prouten, Priya Jalota
A case of persistent diarrhoea Dr. Miles Levy, Dr. Jenny Prouten, Priya Jalota Presentation 58 year old male with 3/12 history of persistent change in bowel habit following trip to India in January 2012
More informationWhat s New in Carcinoid Syndrome? Emily Bergsland Neuroendocrine Tumor PaBent EducaBon Conference
What s New in Carcinoid Syndrome? Emily Bergsland 10.12.13 Neuroendocrine Tumor PaBent EducaBon Conference Overview Carcinoid Syndrome Management Special topics: Refractory diarrhea Carcinoid Crisis/PerioperaBve
More informationSIRT in the Management of Metastatic Neuroendocrine Tumors
SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,
More informationlutetium ( 177 Lu) oxodotreotide 370MBq/mL solution for infusion (Lutathera ) SMC No 1337/18 Advanced Accelerator Applications
lutetium ( 177 Lu) oxodotreotide 370MBq/mL solution for infusion (Lutathera ) SMC No 1337/18 Advanced Accelerator Applications 8 June 2018 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationReview Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Hindawi International Journal of Surgical Oncology Volume 2017, Article ID 6424812, 14 pages https://doi.org/10.1155/2017/6424812 Review Article Management Options for Advanced Low or Intermediate Grade
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationPeptide Receptor Radionuclide Therapy (PRRT) of NET
Peptide Receptor Radionuclide Therapy (PRRT) of NET Dr. Tuba Kendi Associate Prof of Radiology, Mayo Clinic, Rochester, MN 2014 MFMER slide-1 Relevant Financial Relationship(s) None Off Label Usage None
More informationLong-Term Management of a Patient with Well-Differentiated Pulmonary Neuroendocrine Carcinoma: A Case Report
Published online: April 6, 2013 1662 6575/13/0061 0209$38.00/0 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license),
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More informationColor Codes Pathology and Genetics Medicine and Clinical Pathology Surgery Imaging
Saturday, November 5, 2005 8:30-10:30 a. m. Poorly Differentiated Endocrine Carcinomas Chairman: E. Van Cutsem, Leuven, Belgium 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders:
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationUse of Lanreotide (long acting Somatostatin analogue) in Congenital Hyperinsulinism (CHI)
Use of Lanreotide (long acting Somatostatin analogue) in Congenital Hyperinsulinism (CHI) Dr Pratik Shah Clinical Research fellow in Hyperinsulinism Clinical Molecular Genetics Unit Institute of Child
More informationGEP NEN. Personalised approach. Curative and Palliative Surgery. ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano April 2018
GEP NEN Personalised approach Curative and Palliative Surgery ESMO Preceptorship Programme Neuroendocrine Neoplasms Lugano 13 14 April 2018 Professor Andrea Frilling Department of Surgery and Cancer Imperial
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationAdvanced typical and atypical carcinoid tumours of the lung: management recommendations
REVIEW ARTICLE Advanced typical and atypical carcinoid tumours of the lung: management recommendations B. Melosky md* ABSTRACT Background Neuroendocrine tumours (nets) are classified by site of origin,
More informationChair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Public slides Chair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease 2 nd Appraisal Committee meeting Committee
More information*Bert Bakker was an employee of Novartis Pharmaceuticals Corporation until June 06, 2014.
Page 1 of 20 Accepted Preprint first posted on 15 September 2015 as Manuscript ERC-15-0314 1 2 Efficacy of Octreotide LAR in Neuroendocrine Tumors: RADIANT-2 Placebo Arm Post Hoc Analysis 3 4 Authors:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 REMOVAB 10 microgram concentrate for infusion solution Carton containing 1 pre-filled syringe (CIP:
More informationPRESS RELEASE. Lanreotide (Somatuline Autogel ) is featured in 17 presentations: ABSTRACTS SELECTED FOR ORAL PRESENTATIONS
PRESS RELEASE Ipsen announces data presentations of lanreotide (Somatuline Autogel ), telotristat ethyl and the investigational compound 177 Lu-OPS201 at the European Neuroendocrine Tumor Society (ENETS)
More informationNeuroendocrine Tumors
Carcinoid tumours: origin Neuroendocrine Tumors THE A, B,C s Bronchopulmonary system Other 8% 28% Carcinoid site Digestive system 64% 2.3 28 28.5 Other Colon and rectum Small intestine Colon, except appendix
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More information